Recombinant Human DFF-45 Protein, HEK293

Protein-protein Interaction, Post-translational Modifications, ELISA, EIA, Western Blotting, Dot Blotting, Immunoprecipitation, Protein Array, etc.

N-terminal histidine tag

-20°C

Recombinant Human DFF-45, derived from the transfected human HEK293 cells.

DFFA

Lyophilized from a 0.2 µm filtered solution in PBS

DFF-45, DNA fragmentation factor subunit alpha, DNA fragmentation factor 45 kDa subunit, DFF-45, Inhibitor of CAD, ICAD, DFF45, DFF1, DNA Fragmentation Factor Alpha Polypeptide

His-tag affinity purification by immobilized metal ion affinity chromatography (IMAC)

Briefly spin the vial and bring the contents to the bottom prior to opening. It is recommended to reconstitute at 0.5 - 1.0 mg/mL with sterile deionized water.

Figure 1. Deglycosylation of purified recombinant proteins. Purified proteins were untreated (Lane 2) or treated with protein deglycosylation enzymes under native (Lane 3) or reducing (Lane 4) conditions. Deglycosylation treatment resulted in a mobility shift of the protein to produce one major band at the expected size, thus indicating that the untreated recombinant protein (Lane 2) was glycosylated.Lane 1: Protein standard ladder (kDa).Lane 2: Untreated protein under reducing conditions.Lane 3: Treated protein with deglycosylation enzymes under native conditions.Lane 4: Treated protein with deglycosylation enzymes under reducing conditions.Lane 5: Deglycosylation mixture only without target proteins.